Active Immunization with Lipopolysaccharide Pseudomonas Antigen for Chronic Pseudomonas Bronchopneumonia in Guinea Pigs
- 1 November 1981
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 68 (5) , 1140-1148
- https://doi.org/10.1172/jci110358
Abstract
Chronic respiratory infection with Pseudomonas aeruginosa is a leading clinical problem among patients with cystic fibrosis. Because antimicrobial agents are usually ineffective in eradicating these infections, additional therapeutic or prophylactic measures should be considered. In this study, an experimental guinea pig model of chronic Pseudomonas aeruginosa bronchopneumonia was utilized to determine whether active immunization with lipopolysaccharide (LPS) P. aeruginosa antigen may favorably influence the course of this infection. Experimental pneumonia was established by tracheobronchial instillation of suspensions of microscopic agar beads, which were impregnated with viable P. aeruginosa. After 4 wk of infection, the geometric mean (reciprocal) passive hemagglutinating Pseudomonas antibody titer was 185±1.3, and lungs contained 16.8±4 × 103 colony-forming units Pseudomonas/ml of lung homogenate. Pseudomonas immunization, given prior to a 4-wk infection, resulted in significantly higher passive hemagglutinating titers (474±1.4; P < 0.05), lower numbers of viable Pseudomonas in lung tissues (2.4±0.6 × 103; P < 0.01), and reduced histopathology in lungs. In contrast, providing Pseudomonas immunization to animals 2 wk after pulmonary infection was established, offered no apparent benefit. Likewise, no protection was afforded by prophylactic immunization with a non-Pseudomonas LPS antigen (Escherichia coli J5 vaccine). Using a Raji cell assay, modified to detect circulating immune complexes in vaccinated and infected guinea pig sera, there was no evidence that active immunization increased the frequency of circulating immune complexes in infected guinea pigs.It is concluded that prophylactic immunization with Pseudomonas LPS antigen may confer protection from subsequent Pseudomonas bronchopneumonia, but that immunization during established infection is not beneficial.This publication has 39 references indexed in Scilit:
- Mechanism for Pulmonary Protection by Lipopolysaccharide Pseudomonas VaccineThe Journal of Infectious Diseases, 1980
- Circulating Immune Complexes in Cystic FibrosisPediatric Research, 1980
- Hypogammaglobulinemia in Patients with Cystic FibrosisNew England Journal of Medicine, 1980
- Lipopolysaccharide Pseudomonas Vaccine: Efficacy Against Pulmonary Infection with Pseudomonas aeruginosaThe Journal of Infectious Diseases, 1979
- Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.Journal of Clinical Investigation, 1979
- Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages.Journal of Clinical Investigation, 1975
- Type-specific immunity in pseudomonas diseases.1972
- OBSERVATIONS IN CYSTIC FIBROSIS OF PANCREAS .3. PULMONARY LESIONS1968
- BIOLOGIC ACTIVITIES OF AGGREGATED GAMMA-GLOBULIN .8. AGGREGATED IMMUNOGLOBULINS OF DIFFERENT CLASSES1967
- A Method of Trace Iodination of Proteins for Immunologic StudiesInternational Archives of Allergy and Immunology, 1966